Author: Fiona Craig
-
Semiconductor Stocks Climb as Nvidia Prepares to Resume China Sales
Shares in semiconductor companies surged Tuesday following Nvidia’s (NASDAQ:NVDA) announcement that it expects to soon restart sales of its AI-powered chips in China. Ahead of U.S. market open, Nvidia’s stock rallied over 5%, boosting related firms such as Advanced Micro Devices (NASDAQ:AMD), Micron (NASDAQ:MU), Broadcom (NASDAQ:AVGO), and Marvell (NASDAQ:MRVL). European semiconductor leaders—including ASML (EU:ASML), ASM…
-
Dollar Dips Slightly Before Crucial U.S. Inflation Data Release
The U.S. dollar eased marginally on Tuesday but stayed near a three-week peak as markets awaited key inflation figures that could shape the Federal Reserve’s next moves on interest rates. At 04:30 ET (08:30 GMT), the Dollar Index—which tracks the dollar against six major currencies—fell 0.1% to 97.63, just below its highest point since late…
-
Dow Jones, S&P, Nasdaq, Futures Steady as Investors Eye Bank Earnings, Inflation Data, and Nvidia’s China Developments
U.S. equity futures edged slightly higher early Tuesday as markets geared up for a high-stakes session featuring earnings reports from top Wall Street banks and the latest consumer inflation data. Investors are also digesting upbeat growth figures from China and a key update from Nvidia regarding its AI chip sales in the Chinese market. Markets…
-
Gold Rises on Trade War Jitters and Uneven Chinese Economic Indicators
Gold prices moved slightly higher in early Asian trading on Tuesday, buoyed by persistent trade tensions and investor unease over mixed economic signals from China. Growing uncertainty around U.S. President Donald Trump’s aggressive tariff strategy continued to drive safe-haven demand, while patchy Chinese data further reinforced a cautious market tone. Heightened geopolitical risks also lent…
-
Oil Prices Edge Lower as Traders Weigh Trump’s Russia Ultimatum and China’s Q2 Growth
Oil prices dipped slightly during Tuesday’s early trading hours in Asia as markets absorbed two major geopolitical and economic developments: a fresh ultimatum from U.S. President Donald Trump to Russia over the war in Ukraine and a mixed batch of second-quarter economic data out of China. By 21:56 ET (01:56 GMT), Brent crude futures for…
-
BlackRock Stock Hits All-Time High at $1,106.71
BlackRock Inc (NYSE:BLK) reached a record high of $1,106.71, marking a 34.15% gain over the past year. The asset management giant’s strong performance is supported by robust revenue growth of 14.23% and a solid dividend yield of 1.89%. With a market capitalization of $171.18 billion and a P/E ratio of 26.61, BlackRock continues to attract…
-
Takeda Stock Gains 3.5% After Positive Phase 3 Results for Narcolepsy Drug
Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results for its investigational narcolepsy treatment, oveporexton. The Japanese pharma giant reported that oveporexton, a potential first-in-class oral orexin receptor 2 agonist, met all primary and secondary endpoints in two Phase 3 studies—FirstLight and RadiantLight—showing statistically significant symptom…
-
Planet Fitness Stock Hits Record High at $110.95 Amid Strong Growth
Planet Fitness Inc. (NYSE:PLNT) shares surged to an all-time high of $110.95, reflecting a significant milestone for the fitness chain. The company’s market capitalization stands at approximately $9.25 billion, supported by robust gross profit margins nearing 60%. Over the past year, the stock has gained over 44%, driven by growing membership numbers and strategic expansion…
-
Wendy’s Stock Hits 52-Week Low Amid Industry Headwinds and Leadership Changes
Wendy’s Co. (NASDAQ:WEN) shares fell to a 52-week low of $10.93, down more than 30% from last year’s high of $20.60, marking a steep decline for the fast-food chain. This drop reflects both sector-wide pressures and company-specific challenges. Despite the stock’s slump, Wendy’s fundamentals remain solid, with a price-to-earnings ratio of 11.7 and a dividend…
-
BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment
BiomX Inc. (AMEX:PHGE) saw its stock jump 60% after announcing the commencement of patient dosing in its Phase 2b clinical trial evaluating BX004 for cystic fibrosis patients suffering from chronic Pseudomonas aeruginosa infections. This randomized, double-blind, placebo-controlled study will enroll around 60 cystic fibrosis patients, who will receive either BX004 or a placebo via inhalation…